<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public" slc-id="S1-KEN25320-SW1-L0-4WF"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 S1414 IS: Expedited Access to Biosimilars Act</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2025-04-10</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">II</distribution-code><congress>119th CONGRESS</congress><session>1st Session</session><legis-num>S. 1414</legis-num><current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber><action><action-date date="20250410">April 10, 2025</action-date><action-desc><sponsor name-id="S348">Mr. Paul</sponsor> introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSHR00">Committee on Health, Education, Labor, and Pensions</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title>To amend the Public Health Service Act to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy.</official-title></form><legis-body><section id="S1" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Expedited Access to Biosimilars Act</short-title></quote>.</text></section><section id="id76ab6af52cc4485d854e7366ee73be51"><enum>2.</enum><header>Assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy in clinical studies required for licensure of biological products as biosimilar</header><subsection id="idf6c498e35833455299e3b3aacc99896e"><enum>(a)</enum><header>In general</header><text>Section 351(k)(2)(A) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(k)(2)(A)</external-xref>) is amended—</text><paragraph id="id47b3b2b58bf346fdbcef7b374d54755a"><enum>(1)</enum><text>in clause (i)(I)—</text><subparagraph commented="no" display-inline="no-display-inline" id="ida4d7032c3bf348b080ccb7c0cfcc5383"><enum>(A)</enum><text display-inline="yes-display-inline">in item (bb), by striking <quote>and</quote> at the end; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id61d7cbb2645845bd87209e184570c8c9"><enum>(B)</enum><text display-inline="yes-display-inline">by striking item (cc) and inserting the following</text><quoted-block style="OLC" display-inline="no-display-inline" id="id6fa803b02e6647d38c71c9b11fa92b4f"><item id="id962ce2acce8d4ed6801bd811f1b0490b"><enum>(cc)</enum><text>a clinical study or studies assessing pharmacokinetics that are sufficient to demonstrate safety, purity, and potency; and</text></item><item commented="no" display-inline="no-display-inline" id="idc36e11e392b34eab9e7b2793f947337c"><enum>(dd)</enum><text display-inline="yes-display-inline">subject to clause (iv), a clinical study or studies that are sufficient to demonstrate safety, purity, and potency in 1 or more appropriate conditions of use for which the reference product is licensed and intended to be used and for which licensure is sought for the biological product;</text></item><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id1c4f19fa2b724cb1b6f44ed5efb376c6"><enum>(2)</enum><text>by adding at the end the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="id0a33d736f4124acca30804c9c3e85ebf"><clause id="id555aac28993d41b087bb57e76e297305"><enum>(iv)</enum><header>Clinical studies</header><subclause commented="no" display-inline="no-display-inline" id="id8776d2e705d04e65a6e2af99bbf9e92f"><enum>(I)</enum><header>In general</header><text display-inline="yes-display-inline">Subject to subclause (II), the Secretary may determine, in the Secretary's discretion, that a clinical study required under clause (i)(I)(dd) shall include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy. </text></subclause><subclause commented="no" display-inline="no-display-inline" id="idda1b91ca0ff8466ba8e2c7b0fccf461a"><enum>(II)</enum><header>Requirement</header><text display-inline="yes-display-inline">The Secretary may only require the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy pursuant to a determination under subclause (I) if the Secretary provides to the applicant notice of the requirement, including a written justification of the basis for such determination, not later than the earliest date on which the applicant may file the application under this subsection.</text></subclause></clause><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="id295a150bb15a4ae8aa72e2bcfe93213b"><enum>(b)</enum><header>Applicability</header><text>The amendments made by subsection (a) shall apply with respect to an application submitted under section 351(k) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(k)</external-xref>) on or after the date of enactment of this Act. </text></subsection></section></legis-body></bill> 

